表纸
市场调查报告书

过去十年中的传染病大流行

Pandemic Outbreaks in the Past Decade: A BCC Research Overview

出版商 BCC Research 商品编码 940537
出版日期 内容资讯 英文 76 Pages
订单完成后即时交付
价格
过去十年中的传染病大流行 Pandemic Outbreaks in the Past Decade: A BCC Research Overview
出版日期: 2020年06月02日内容资讯: 英文 76 Pages
简介

本报告调查了过去10年中全球传染病的流行情况,以及过去主要传染病的流行情况以及病原微生物,爆发因素,流行病学,病理生理学,诊断/评估方法,治疗它总结了管理法律,国家和国际努力以及从过去的大流行中汲取的经验教训。

第1章简介

第2章:全球传染病大流行:简介

  • 致病微生物和传染病:1973-2019年
  • 导致传染病爆发的因素
  • 病毒爆发,流行和大流行的分类
  • 当前的时尚和潜力□全球时尚的潜力
  • 当前的大流行和潜力
  • 当前的应对技术
  • 恐怖主义生物武器
  • 下一个全球流行病
  • 人畜共患病毒的类型
  • 传染病全球流行:历史
  • 传染病治疗

第3章H1N1流感(猪流感)

  • 病因
  • 流行病学
  • 病理生理学
  • 流感病毒的类型
    • 甲型流感病毒
    • 乙型流感病毒
    • C型流感病毒
  • 诊断与评估
  • 治疗/管理
  • 世界卫生组织和收容措施
  • 流感疫苗库存
  • 流行前疫苗接种
  • 抗病毒性
  • 再生病毒
  • 无形的市场风险
  • 媒体报导和疫苗接种
  • 主要国家的国家计划

第4章埃博拉病毒病

  • 病因
  • 流行病学
  • 临床症状
  • 诊断
  • 治疗/管理

第5章MERS(中东呼吸综合征)

  • 病因
  • 流行病学
  • 病理生理学
  • 临床特征
  • 诊断
  • 治疗/管理
  • 预防
  • 优先级:MERS的研究,监控,管理和控制

第6章新的冠状病毒感染(SARS-CoV-2)

  • COVID-19症状
  • COVID-19的进展
  • 潜伏期
  • 流行病学
  • 研发
  • 诊断/医疗技术
  • 需要重新设计呼吸机
  • COVID-19临床试验

第7章过去的经验教训

  • 维持基本医疗服务
  • 获得预防/安全措施/测试/治疗的途径
  • 隔离与分离
  • 国际努力加强全球爆发对策系统

第8章附录

目录
Product Code: PHM232A

Highlights:

This report focuses on epidemiology, research and development, current treatment and diagnostics and global response to selected pandemics of the past decade (2009-2020). The report discusses lessons learned from previous outbreaks in terms of policies and measures of prevention and control.

Report Includes:

  • An overview of the pandemic outbreaks occurred over the last decade (2010-2020)
  • Discussion of several serious epidemiological outbreaks, their socioeconomic impact, R&D efforts, treatment and diagnostics, clinical trial landscape, and regulatory and reimbursement landscape
  • Data corresponding to number of confirmed cases and reported deaths (globally and country wise) due to various pandemics, including novel coronavirus disease (COVID-19), SARS, MERS, HIV/AIDS, H1N1, Ebola virus etc.
  • Correlation of coronavirus (Covid-19) outbreak to previous epidemiological outbreaks in terms of policies and measures of prevention and control, and the lessons learned thereafter
  • Insight into key scientific breakthroughs and pipeline products targeting infectious disease treatments, including the novel coronavirus disease and its antibody-based clinical program (antibody to MERS-CoV infection)

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Introduction to Pandemics

  • Pathogenic Microbes and Infectious Diseases: 1973-2019
  • Factors Contributing to the Emergence of Infectious Diseases
    • Human Demographics and Behavior
    • Technology
    • The Role of Needles
    • Economic Development and Land Use
    • International Travel
    • Microbial Adaptation
    • Antibiotic Development
  • Classifying Viral Outbreaks, Epidemics and Pandemics
  • Current and Potential Epidemics with Pandemic Potential
  • Current and Potential Pandemics
  • Current Technologies for Addressing Potential Pandemic Threats
  • Biological Weapons for Terrorism
  • The Next Pandemic
  • Types of Zoonotic Viruses
  • A Brief History of Global Pandemics
    • Bubonic Plague (1300 to the Present)
    • Cholera (1916-1966)
    • The Spanish Influenza Pandemic (1918)
    • Asian Flu Pandemic (1957-1958)
    • HIV/AIDS Pandemic (1980 to the Present)
    • Influenza A-H1N1 (2009 to the Present)
    • Malaria (2700 BC to the Present)
    • Severe Acute Respiratory Syndrome (SARS) (2002-2003)
    • Tuberculosis (4000 BC to the Present)
  • Treatments for Infectious Diseases
    • Prevention
    • Vaccination
    • Pharmaceutical Treatments

Chapter 3: H1N1 Influenza (Swine Influenza)

  • Etiology
  • Epidemiology
  • Pathophysiology
  • Types of Influenza Viruses
    • Influenza Virus A
    • Influenza Virus B
    • Influenza Virus C
  • Diagnosis and Evaluation
    • Real-Time Polymerase Chain Reaction
    • Nucleotide Sequencing
    • Phylogenetic Analysis
  • Treatment and Management
    • Prevention of Swine to Human Viral Transmission
    • Prevention of Human-to-Human Transmission
    • Vaccines
    • Antiviral Treatments
  • The WHO and Containment for Pandemic Influenza
  • International Influenza Vaccine Stockpile Orders
  • Pre-pandemic Vaccination
    • Biomedical Advanced Research and Development Authority (BARDA)
  • Antiviral Resistance
  • Recreated Viruses
  • Immaterialized Market Risk
  • Media Coverage and Vaccinations
  • Pandemic Preparedness Plans
    • United States
    • Japan
    • China
    • Brazil
    • United Kingdom

Chapter 4: Ebola Virus Disease

  • Etiology
  • Epidemiology
  • Clinical Manifestations
  • Diagnosis
  • Treatment/Management
    • Supportive Care
    • Therapeutics
    • Vaccines and Prevention

Chapter 5: Middle East Respiratory Syndrome

  • Etiology
  • Epidemiology
    • Geographical Distribution
    • Sources of Infection
    • Risk Factors and Transmission
  • Pathophysiology
  • Clinical Features
  • Diagnosis
    • Molecular Diagnostics
    • Serological Assays
  • Treatment and Management
    • Antiviral Agents
    • Convalescent Plasma
    • Antibiotic Therapy
    • Intensive Care Management
    • New Treatments
  • Prevention
    • Advances in Vaccine Development
  • Priorities: MERS Research, Surveillance, Management, and Control
    • Establishing a One Health Global Consortium
    • Priority Studies at the Animal-Human-Environmental Interface
    • Priority Studies in Human Populations
    • Priority Studies for Vaccines, Therapeutics, and Rapid Diagnostics

Chapter 6: Coronavirus Disease 2019 (SARS-CoV-2)

  • Symptoms of COVID-19
  • COVID-19 Progression
  • Incubation Period
  • Epidemiology
    • Case Fatality Rate (CFR)
    • Global Confirmed Cases and Confirmed Deaths Due to COVID-19
  • COVID-19 Research and Development
  • Diagnostics and Medtech
  • The Need to Reinvent Ventilators
  • Clinical Trials on COVID-19

Chapter 7: Lessons Learned from History

  • Maintaining Essential Healthcare Services
  • Access to Prevention, Safety Measures, Testing and Treatment
  • Quarantine and Isolation
  • International Efforts to Strengthen the Global Outbreak Response System
    • Africa Centers for Disease Control and Prevention
    • Coalition for Epidemic Preparedness Innovations
    • European Medical Corps
    • Regional Disease Surveillance Systems Enhancement Program
    • The WHO Global Health Emergency Workforce
    • The WHO R&D Blueprint
    • World Bank Pandemic Emergency Financing Facility

Chapter 8: Appendix

  • Acronyms

List of Tables

  • Table 1: Pathogenic Bacteria, Parasites and Viruses, 1973-2019
  • Table 2: History of Antibiotic Discovery and Approval, 1935-2013
  • Table 3: CDC: Six Phases of Classification of Viral Pandemics
  • Table 4: Technologies for Addressing Potential Pandemic Threats
  • Table 5: Diseases That Have Been or Can Be Weaponized
  • Table 6: Commercial Products of H1N1 Influenzas Diagnostics
  • Table 7: Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
  • Table 8: Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
  • Table 9: Japan's Action Plan for Influenza Pandemic Preparedness
  • Table 10: China's Influenza Pandemic Warning Levels
  • Table 11: Brazil's Influenza Pandemic Warning Levels and Action
  • Table 12: Ebola Outbreaks Between 1976 and 2014
  • Table 13: Clinical Features of Ebola Virus Disease, by Stage
  • Table 14: Overview of Investigational Therapeutics Evaluated in Clinical Trials on Ebola Virus Disease During the 2013-2016 West African Outbreak
  • Table 15: Key Vaccines with Accelerated Clinical Development During the 2013-2016 Ebola Virus Disease Outbreak
  • Table 16: Molecular Diagnostic Tests for MERS-CoV Diagnosis, Single Assays
  • Table 17: Molecular Diagnostic Tests for MERS-CoV Diagnosis, Multiplex Assays
  • Table 18: Serology Tests for MERS-CoV Diagnosis
  • Table 19: Potential Therapies for MERS-CoV Infection
  • Table 20: Vaccines in the Pipeline for the Prevention of MERS-CoV Infection
  • Table 21: COVID-19 Symptoms by Percentage of Patients
  • Table 22: Case Fatality Rate of COVID-19, by Region, March 2020
  • Table 23: Case Fatality Rate of COVID-19, by Selected Country
  • Table 24: COVID-19: Confirmed Cases and Deaths, by Country, May 14, 2020
  • Table 25: COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Companies in Collaboration
  • Table 26: COVID-19 Therapeutics in Development, by Biopharmaceutical Company
  • Table 27: COVID-19 Vaccines in Development, by Biopharmaceutical Companies in Collaboration
  • Table 28: COVID-19 Vaccines in Development, by Biopharmaceutical Company
  • Table 29: Modifiable Breathing Devices Eligible for EUAs, by Company
  • Table 30: Number of Clinical Trials on COVID-19, by Phase
  • Table 31: Number of Clinical Trials on COVID-19, by Intervention
  • Table 32: Clinical Trials on COVID-19, by Country
  • Table 33: High-Level Initiatives Established Since the Ebola Crisis
  • Table 34: List of Acronyms

List of Figures

  • Figure 1: Number of Approved WHO Influenza Centers, by WHO Dedignated Region
  • Figure 2: Targeted Pre-pandemic Influenza Vaccine Stockpiles Based on Population Demand for Selected Countries
  • Figure 3: Geographical Distribution of Reported Human Infections of MERS-CoV
  • Figure 4: Infographic Comparison of CFR and Cases of the Three Major Beta Coronaviruses: MERS, SARS, and COVID-19
  • Figure 5: Distribution of Clinical Trials on COVID-19, by Phase
  • Figure 6: Distribution of Clinical Trials on COVID-19, by Intervention
  • Figure 7: Distribution of Clinical Trials on COVID-19, by Country
  • Figure 8: The Role of High-Level Initiatives in Enhancing the Three Main Phases of Global Outbreak Preparedness